Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026)

Arcus Biosciences' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 16.92% year-over-year to $997.0 million in Q1 2026; TTM through Mar 2026 was $4.2 billion, a 13.71% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 0.96% from the prior year.
• Liabilities and Shareholders Equity retreated to $997.0 million in Q1 2026 per RCUS's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q1 2022 and bottomed at $974.0 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 66.07% in 2022 and declined 25.08% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then declined by 15.77% to $1.1 billion in 2023, then gained by 5.02% to $1.2 billion in 2024, then fell by 0.96% to $1.1 billion in 2025, then dropped by 12.47% to $997.0 million in 2026.
• Per Business Quant, the three latest RCUS Liabilities and Shareholders Equity figures stand at $997.0 million (Q1 2026), $1.1 billion (Q4 2025), and $974.0 million (Q3 2025).